Dora Biotechnology

What Dora Biotechnology does

Dora Biotechnology is a Turkey-based tissue bank operating under the trade names Dora Biyoteknoloji, Dora Biologics, and Avrasya Doku Bankası (Eurasia Tissue Bank). Founded in 2014 and headquartered in Çankaya, Ankara, the company processes and supplies allograft tissues for surgical use, serving hospitals, orthopedic clinics, surgical centers, and individual surgical specialists in Turkey and (on a limited basis) continental Europe via a registered office in Berlin. Its customer approach is horizontal, organized around tissue need rather than surgical specialty, with quote-based pricing that is not publicly disclosed.

The company's core offering is a ten-product allograft portfolio spanning musculoskeletal grafts (granular and powder bone, structural bone, demineralized bone matrix, osteochondral, meniscus, costal cartilage), biological membranes (fascia lata, pericardium, amniotic membrane), and soft-tissue matrices (the trademarked Allomore® adipose matrix product). These products are complemented by three vertically integrated services — tissue processing, controlled-temperature storage, and delivery — making Dora a full-service tissue bank rather than a pure product supplier. Distribution is direct to healthcare institutions, and the company markets through a product-catalog website (dorabiologics.com) and social media channels (Facebook, LinkedIn, Instagram).

No revenue, headcount trend, funding history, ownership structure, management team, patents, certifications, or partnerships are disclosed in the available source material, and the website content is primarily in Turkish, indicating domestic-market concentration. The company's product breadth and decade-plus operating history suggest a functioning small-scale tissue bank, but the data gap on financial and organizational specifics limits visibility into scale, capital structure, and growth dynamics.

Name

Dora Biotechnology

Legal name

Dora Biyoteknoloji

Website

https://doramedical.net

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Dora Biotechnology is a Turkey-based tissue bank (Avrasya Doku Bankası) that processes and supplies allograft tissues across ten product lines, serving hospitals, orthopedic clinics, and surgical specialists in Turkey and Europe.

Ownership category

akta.pro rank

Product category

Allograft Tissue Products

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Medical Equipment and Supplies Manufacturing (3391)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)

akta.pro secondary industries

Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH), Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

Keywords

• Allograft tissue products
• Bone graft processing
• Demineralized bone matrix
• Tissue banking services
• Surgical membrane allografts

Headquarters

HQ city

Çankaya

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure

Distribution channels1 record

Marketing channels4 records

Core offering

Dora Biotechnology (operating as Dora Biyoteknoloji, Dora Biologics, and the Avrasya Doku Bankası / Eurasian Tissue Bank) processes and supplies human allograft tissue products for surgical use. The portfolio includes granular and structural bone grafts, demineralized bone matrix (DBM), osteochondral grafts, meniscus allografts, fascia lata and pericard membranes, costal cartilage, amniotic membrane grafts, and the branded Allomore® adipose matrix allograft, complemented by tissue processing, controlled-temperature storage, and delivery services.

Product overview

Dora Biotechnology (Dora Biyoteknoloji) is a tissue bank operating as the Eurasia Tissue Bank (Avrasya Doku Bankası). The company offers a comprehensive portfolio of allograft products and services. The core product portfolio includes 10 distinct allograft types: Granular/Powder Bone Allografts, Structural Bone Grafts, Demineralized Bone Matrix (DBM) products, Osteochondral Grafts, Meniscus Allografts, Fascia Lata Membranes, Pericard Membranes, Costal Cartilage Allografts, Amniotic Membrane Allografts, and the branded Allomore Adipose Matrix Allograft. These tissue products are complemented by three supporting services: Tissue Processing, Storage, and Delivery services. The portfolio spans musculoskeletal grafts (bone, cartilage, meniscus), biological membranes (fascia, pericardium, amniotic), and specialized allografts for reconstructive and regenerative medicine applications.

Differentiator

Problem solved

Functional benefit

Brands

• Allomore®: Adipose matrix allograft product

Products and services

• Granular/Powder Bone Allografts (Granül/Toz Kemik Allogreftleri)

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Recent moves4 records

Expansion highlights3 records

Direct peers

• MTF Biologics: One of the largest US-based tissue banks, supplying bone grafts, DBM, osteochondral, meniscus, amniotic membrane and sports medicine allografts — directly comparable to Dora's full musculoskeletal and membrane portfolio.
• LifeNet Health: Non-profit tissue processor offering bone allografts, DBM, dermal matrices and sports medicine grafts; competes with Dora across orthopedic and wound healing allograft categories.
• Surgenex: Tissue processor offering amniotic membrane and other regenerative allografts for wound healing and orthopedic applications; competes with Dora's amniotic and soft-tissue products.
• Xtant Medical: Specialty orthobiologics company focused on bone grafts, DBM and sports medicine allografts, including spinal and extremity applications — comparable scale and product mix to Dora.
• RTI Surgical: Commercial allograft and orthopedic implant company offering bone grafts, DBM and soft-tissue matrices; overlaps directly with Dora's orthopedic and reconstructive allograft lines.
• AlloSource: US tissue bank producing bone, cartilage, meniscus, skin and amniotic allografts for orthopedic and wound-care use — closely mirrors Dora's product breadth.

Broad incumbents

• Bioventus: Orthobiologics-focused company offering bone graft substitutes and regenerative products across orthopedic and spine surgery; comparable to Dora's bone and DBM lines.
• Integra LifeSciences: Diversified medical device company with orthobiologics and regenerative tissue products (including dermal matrices) that overlap with Dora's bone, membrane and amniotic offerings.
• Smith+Nephew: Global medical device major with an orthobiologics portfolio spanning bone grafts and regenerative technologies; competes with Dora in sports medicine and reconstructive surgery.
• SeaSpine (Orthofix): Spine and orthopedics company with allograft and DBM spinal fusion products, competing with Dora's DBM and structural bone lines in spinal applications.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks7 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/dorabiyoteknoloji
• LinkedInlinkedin.com/company/dorabiyoteknoloji
• Instagraminstagram.com/dorabiyoteknoloji

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dora Biotechnology